Entyvio（クローン病治療薬）：市場予測及び分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Symptoms 16
3.3 Prognosis 17
3.4 Quality of Life 17
4 Disease Management 18
4.1 Treatment Overview 19
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 25
6 Opportunity and Unmet Need 27
6.1 Overview 27
6.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 28
6.3 More Therapies for Anti-TNF-Refractory Patients 29
6.4 Unmet Needs Gap Analysis 30
6.5 Targeted Therapies 31
6.6 Predictive Tools for Early Diagnosis and Treatment 32
7 Pipeline Assessment 33
7.1 Overview 33
7.2 Promising Drugs in Clinical Development 33
8 Entyvio (vedolizumab) 36
8.1 Overview 36
8.2 Efficacy 37
8.3 Safety 40
8.4 Dosing and Formulation 42
8.5 Potential Clinical Positioning 43
8.6 Potential Commercial Positioning 45
8.7 Pricing and Reimbursement 45
8.8 SWOT Analysis 46
8.9 Forecast 47
9 Appendix 49
9.1 Bibliography 49
9.2 Abbreviations 52
9.3 Methodology 55
9.4 Forecasting Methodology 55
9.4.1 Diagnosed CD Patients 55
9.4.2 Percent Drug-Treated Patients 56
9.4.3 General Pricing Assumptions 56
9.4.4 Generic Erosion 58
9.4.5 Pricing of Pipeline agents 58
9.5 Physicians and Specialists Included in This Study 59
9.6 Primary Research – Prescriber Survey 61
9.7 About the Authors 62
9.7.1 Author/Reviewer 62
9.7.2 Global Head of Healthcare 62
9.8 About GlobalData 63
9.9 Disclaimer 63